Антагонисты кальция и прогрессирование почечнойнедостаточности

1. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
3. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST), a randomized controlled trial. JAMA 2003; 290: 2805–16.
4. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757–64.
5. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet 1999; 354: 1751–6.
6. Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–65.
7. Liu L, Wang JG, Gong L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823–9.
8. Gong L, Zhang W, Zhu Y et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237–45.
9. Meredith PA, Eliott HL. Dihydropyridine calcium channel blockers: Basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 2004; 22: 1641–8.
10. Herbette LG, Gaviraghi G, Tulenko T, Mason RP. Molecular interaction between lacidipine and biological membranes. J Hypertens Suppl 1993; 11: S13–9.
11. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and endstage renal disease in men. N Engl J Med 1996; 334: 13–8.
12. Ruilope LM, Campo C, Rodriguez-Artalejo F et al. Blood pressure and renal function: Therapeutic implications. J Hypertens 1996; 14: 1259–63.
13. Mandhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet 1995; 345: 749–51.
14. Sweeney C, Shultz P, Raij L. Interactions of the endothelium and mesangium in glomerular injury. J Am Soc Nephrol 1990; 1: S13–20.
15. Raij L, Keane W. Glomerular mesangium: Its function and relationship to angiotensin II. Am J Med 1985; 79 (Suppl. 36): 24–30.
16. Sugiura T, Imai E, Moriyama T et al. Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: Possible mechanism of suppression of AP-1 and CREB activities. Nephron 2000; 85: 71–80.
17. Ono T, Liu N, Kusano H et al. Broad antiproliferative effects of benidipine on cultured human mesangial cells in cell cycle phases. Am J Nephrol 2002; 22: 581–6.
18. Roth M, Keul R, Emmons LR et al. Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci USA 1992; 89: 4071–5.
19. Hayashi M, Yamaji Y, Nakazato Y, Saruta T. The effects of calcium channel blockers on nuclear factor kappa B activation in the mesangial cells. Hypertens Res 2000; 23: 521–5.
20. Fukuo K, Yang J, Yasuda O et al. Nifedipine indirectly upregulates superoxide dismutase expression in endothelial cells via vascular smooth muscle cell-dependent pathways. Circulation 2002; 106: 356–61.
21. Chen L, Haught WH, Yang B et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of anti-atherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30: 569–75.
22. Lander HR. An essential role for free radicals and derived species in signal transduction. FASEB J 1997; 11: 118–24.
23. Van Amsterdam FTM, Roveri A, Maiorino M et al. Lacidipine: A dihydropyridine calcium antagonist with antioxidant activity. Free Rad Biol Med 1992; 12: 183–7.
24. Cominacini L, Garbin U, Fratta Pasini A et al. Lacidipine inhibits the activation of the transcription factor Nf-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens 1997; 15: 1633–9.
25. Epstein M. Calcium antagonists and renal protection: Emerging perspectives. J Hypertens 1998; 18 (Suppl. 4): S17–25.
26. Brooks DP. Endothelin: The «prime suspect» in kidney disease. News Physiol Sci 1997; 12: 83–9.
27. Fujita K, Matsumura Y, Miyazaki Y et al. ETA receptor-mediated role of endothelin in the kidney of DOCA-salt hypertensive rats. Life Sci 1995; 58: PL1–7.
28. Hocher B, Rohmeiss P, Zart R et al. Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats. Cardiovasc Res 1996; 31: 499–510.
29. Gurbanov K, Rubinstein I, Hoffman A et al. Differential regulation of renal regional blood flow by endothelin-1. Am J Physiol 1996; 271: F1166–72.
30. Tsuchiya K, Naruse M, Sanaka T et al. Effects of endothelin on renal regional blood flow in dogs. Eur J Pharmacol 1989; 166: 541–3.
31. Cowley AW Jr. Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol 1997; 273: R1–15.
32. Bergstr_m G, Evans RG. Effects of renal medullary infusion of a vasopressin V1 agonist on renal antihypertensive mechanisms in rabbits. Am J Physiol 1998; 275: R76–85.
33. Lerman A, Edwards BS, Hallett JW et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997–1001.
34. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4: 303–8.
35. Reams GP, Bauer JH. Acute and chronic effects of calcium antagonists on the essential hypertensive kidney. In: Epstein M, Loutzenhiser R (eds). Calcium Antagonists and the Kidney. Philadelphia: Hanley & Belfus; 1990; 247–56.
36. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545–50.
37. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996; 50: 684–92.
38. Carmines PK, Navar LG. Disparate effects of Ca channel blockers on afferent and efferent arteriolar responses to ANG II. Am J Physiol 1989; 256: F1015–20.
39. Loutzenhiser R, Epstein M. Renal hemodynamic effects of calcium antagonists. In: Epstein M, Loutzenhiser R (eds). Calcium Antagonists and the Kidney. Philadelphia: Hanley & Belfus; 1990; 33–74.
40. Fleming JT, Parekh N, Steinhausen M. Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol 1987; 253: F1157–63.
41. Dworkin LD. Effects of calcium channel blockers on glomerular injury on experimental glomerular injury. J Am Soc Nephrol 1990; 1: S21–7.
42. Kanno Y, Suzuki H, Okada H, Saruta T. Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet. J Cardiovasc Pharmacol 1994; 23: 480–4.
43. Nagahama T, Hayashi K, Fujiwara K et al. Characterization of the renal action of pranidipine in the rat. Arzneimittel-Forsch 2000; 50: 248–53.
44. Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension 1991; 17: 288–95.
45. Bidani AK, Schwartz MM, Lewis EJ. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol1987; 252: F1003–10.
46. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical determinant of subsequent hypertension and glomerular injury. J Am Soc Nephrol 1994; 4: 2023–31.
47. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockers on pressures transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793–800.
48. Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999; 55: 1849–60.
49. Heller J, Horacek V. The effect of two different calcium antagonists on the glomerular haemodynamics in dogs. Eur J Physiol 1990; 415: 751–5.
50. Dietz JR, Davis JO, Freeman RH et al. Effects of intrarenal infusion of calcium entry blockers in anesthetized dogs. Hypertension 1983; 5: 482–8.
51. Abe Y, Komori T, Miura K et al. Effects of the calcium antagonist nicardipine on renal function and renin release in dogs. J Cardiovasc Pharmacol 1983; 5: 254–9.
52. Roy M, Guthrie GP, Holladay FP, Kotchen TA. Effects of verapamil on renin and aldosterone in the dog and rat. Am J Physiol 1983; 245: E410–6.
53. Smith SA, Rafiqi EI, Gardener EG, Young MA, Little WA. Renal effects of nicardipine in essential hypertension: Differences between acute and chronic therapy. J Hypertens 1987; 5: 693–7.
54. Johns EJ. The influence of diltiazem and nifedipine on renal function in the rat. Br J Pharmacol 1985; 84: 707–13.
55. Kimura G, Deguchi F, Kojima S et al. Effect of a calciumentry blocker, nicardipine, on intrarenal hemodynamics in essential hypertension. Am J Kidney Dis 1991; 18: 47–54.
56. Arima S, Ito S, Omata K et al. Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int 1996; 55 (Suppl.): S132–4.
57. Hayashi K, Ozawa Y, Fujiwara K et al. Role of actions of calcium antagonists on efferent arterioles – with special references to glomerular hypertension. Am J Nephrol 2003; 23: 229–44.
58. Takabatake T, Ohta H, Sasaki T, Satoh S et al. Renal effects of manidipine hydrochloride: A new calcium antagonist in hypertensive patients. Eur J Clin Pharmacol 1993; 45: 321–5.
59. Allison N, Dubb J, Alexander P et al. Effect of nilvadipine on renal function in normal man (abstract). Fed Proc 1985; 44: 1638.
60. Yokoyama T, Masuda Y, Sakai T et al. Effects of NZ–105, a new calcium antagonist, on renal function in anesthetized spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992; 19: 851–6.
61. Tojo A, Kimura K, Matsuoka H, Sugimoto T. Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992; 20: 895–9.
62. Arima S, Ito S, Omata K et al. Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int 1996; 55 (Suppl.): S132–4.
63. Morikawa T, Okumura M, Konishi Y et al. Effects of benidipine on glomerular hemodynamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res 2002; 25: 571–6.
64. Hayashi K, Nagahama T, Oka K et al. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 1996; 19: 31–6.
65. Saruta T, Kanno Y, Hayashi K, Konishi K. Antihypertensive agents and renal protection: Calcium channel blockers. Kidney Int 1996; 55 (Suppl. 49): S52–6.
66. Ozawa Y, Hayashi K, Nagahama T et al. Renal afferent and efferent arteriolar dilation by nilvadipine: Studies in the isolated perfused hydronephrotic kidney. J Cardiovasc Pharmacol 1999; 33: 243–7.
67. Ozawa Y, Hayashi K, Nagahama T et al. Effect of T-type selective calcium antagonist on renal microcirculation: Studies in the isolated perfused hydronephrotic kidney. Hypertension 2001; 38: 343–7.
68. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775–9.
69. Ozawa Y, Hayashi K, Oka K et al. Divergent action of calcium antagonists on the efferent arteriole (abstract). J Hypertens 1998; 16 (Suppl. 2): S27.
70. Hansen PB, Jensen BL, Andreasen D, Sk_tt O. Differential expression of T- and L-type voltage- dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630–8.
71. Nakamura Y, Ono H, Frohlich ED. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertension 1999; 34: 273–8.
72. Masumiya H, Tanaka Y, Tanaka H, Shigenobu K. Inhibition of T-type and L- and T- type Ca2+ currents by aranidipine, a novel dihydropyridine Ca2+ antagonist. Pharmacology 2000; 61: 57–61.
73. Masumiya H, Shijuku T, Tanaka H, Shigenobu K. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: Possible mechanism for chronotropic effect. Eur J Pharmacol 1998; 349: 351–7.
74. Nagahama T, Hayashi K, Ozawa Y et al. Role of protein kinase C in angiotensin II-induced constriction of renal microvasculature. Kidney Int 2000; 57: 215–23.
75. Wagner C, Kr_mer KB, Hinder M et al. Ttype and L-type calcium channel blockers exert opposite effects on rennin secretion and renin gene expression in conscious rats. Br J Pharmacol 1998; 124: 579–85.
76. Harris DC, Hammond WS, Burke TJ, Schrier RW. Verapamil protects against progression of experimental chronic renal disease. Kidney Int 1987; 31: 41–6.
77. Dworkin LD, Feiner HD, Parker M, Tolbert E. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991; 9: 1112–7.
78. Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999; 55: 1849–60.
79. Wenzel UO, Troschau G, Schoeppe W et al. Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992; 20: 233–41.
80. Pelayo JC, Westoo JY. Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. J Clin Invest 1991; 88: 101–5.
81. Tarif N, Bakris GL. Preservation of renal function: The spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997; 12: 2244–50.
82. Takakura S, Furuichi Y, Yamamoto T et al. Effects of nilvadipine on the development of neurological deficits in stroke-prone spontaneously hypertensive rats. Stroke 1994; 25: 677–82.
83. Shudo C, Masuda Y, Sugita H et al. Effects of efonidipine, nicardipine and captopril on proteinuria in aged spontaneously hypertensive rats. Arzneimittel-Forsch 1996; 46: 852–4.
84. Fujimaki M, Nagase M, Uchida S. Long-term effect of manidipine on renal function and structure in uninephrectomized spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1997; 24: 506–12.
85. Schnack C, Capek M, Banyai M et al. Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria. Acta Diabetol 1994; 31: 14–8.
86. Voyaki SM, Staessen JA, Thijs L et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001; 19: 511–9.
87. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129–33.
88. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
89. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
90. Bakris GL, Mangrum A, Copley JB et al. Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29: 744–50.
91. Bakris GL, Weir RM, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283–9.
92. Rubio-Guerra AF, Arceo-Navarro A, Vargas-Ayala G et al. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004; 27: 1688–91.
93. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in Type 2 diabetes. N Engl J Med 2004; 351: 1941–51.
94. The PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: A randomized doubleblind trial. J Hypertens 2002; 20: 729–37.
95. Fernandez R, Garcia Puig J, Rodriguez Perez JC et al., on behalf of the TRAVEND Study Group. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria. A randomized, double-blind study. J Human Hypertens 2001; 15: 849–56.
96. Boero R, Rollino C, Massara C et al. The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. Am J Kidney Dis 2003; 42: 67–75.
97. Bitar R, Flores O, Reverte M et al. Beneficial effect of verapamil added to chronic ACE inhibitor treatment on renal function in hypertensive elderly patients. Int Urol Nephrol 2000; 32 (2): 165–9.
98. Macias JF, Fernandez R, Calvo C et al. Verapamil reverts acute renal impairment induced by angiotensin II converting enzyme inhibitors. Ren Fail 2003; 25: 727–37.
99. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001; 285: 2719–28.
100. Marin R, Ruilope LM, Aljama P et al., on behalf of the investigators of the ESPIRAL Study. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001; 19: 1871–6.
101. Baba S, J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54 (3): 191–201.
102. Herlitz H, Harris K, Risler T et al. The effect of an ACE inhibitor and a calcium antagonist in the progression of renal disease: The Nephros Study. Nephrol Dial Transplant 2001; 16: 2158–65.
103. Shigihara T, Sato A, Hayashi K, Saruta T. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes. Hypertens Res 2000; 23: 219–26.
104. Fogari R, Preti P, Zoppi A et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 1042–9.
105. Ruggenenti P, Perna A, Loriga G et al. Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 2005; 365: 939–46.
106. Bellinghieri G, Mazzaglia G, Savica V, Santoro D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: A multicenter randomized controlled trial. Ren Fail 2003; 25: 681–9.
107. Fogari R, Mugellini A, Zoppi A et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol 2005; 61: 483–90.
108. Del Vecchio L, Pozzi M, Salvetti A et al. Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril. J Nephrol 2004; 17: 261–9.
109. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL Study (diabete, ipertensione, albuminuria, lercanidipina). Diab Nutr Metab 2004; 17: 259–66.
110. Robles NR, Ocon J, Gomez Campder_ F et al. Lercanidipine in chronic renal failure patients: The ZAFRA Study. Ren Fail 2005; 27: 73–80.